Advertisement

Topics

Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors

16:23 EDT 29 Jun 2017 | Biotech-Finances

Wednesday, June 28th 2017 at 8:30pm UTC NEW YORK–(BUSINESS WIRE)– Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that it has appointed Rainer Boehm, M.D. and Hervé Hoppenot to its Board of Directors. “We are delighted to welcome Rainer …

Cet article Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of
Directors
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors

NEXT ARTICLE

More From BioPortfolio on "Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...